Protagonist Therapeutics Inc (PTGX)
41.11
+0.07
(+0.17%)
USD |
NASDAQ |
Nov 15, 16:00
41.14
+0.03
(+0.07%)
After-Hours: 20:00
Protagonist Therapeutics Research and Development Expense (TTM): 132.12M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 132.12M |
| June 30, 2024 | 126.82M |
| March 31, 2024 | 126.48M |
| December 31, 2023 | 120.16M |
| September 30, 2023 | 121.15M |
| June 30, 2023 | 115.88M |
| March 31, 2023 | 117.31M |
| December 31, 2022 | 126.22M |
| September 30, 2022 | 134.70M |
| June 30, 2022 | 146.26M |
| March 31, 2022 | 138.08M |
| December 31, 2021 | 126.01M |
| September 30, 2021 | 107.12M |
| June 30, 2021 | 86.16M |
| March 31, 2021 | 79.98M |
| December 31, 2020 | 74.51M |
| September 30, 2020 | 70.93M |
| June 30, 2020 | 72.23M |
| Date | Value |
|---|---|
| March 31, 2020 | 71.33M |
| December 31, 2019 | 65.00M |
| September 30, 2019 | 63.34M |
| June 30, 2019 | 58.19M |
| March 31, 2019 | 56.57M |
| December 31, 2018 | 59.50M |
| September 30, 2018 | 56.97M |
| June 30, 2018 | 56.00M |
| March 31, 2018 | 50.27M |
| December 31, 2017 | 46.18M |
| September 30, 2017 | 43.28M |
| June 30, 2017 | 37.67M |
| March 31, 2017 | 31.36M |
| December 31, 2016 | 25.70M |
| September 30, 2016 | 21.08M |
| June 30, 2016 | 18.67M |
| March 31, 2016 | 15.27M |
| December 31, 2015 | 11.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
65.00M
Minimum
Dec 2019
146.26M
Maximum
Jun 2022
107.92M
Average
118.74M
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 16.41B |
| Assembly Biosciences Inc | 49.97M |
| Precision BioSciences Inc | 57.04M |
| Entrada Therapeutics Inc | 120.19M |
| NovaBay Pharmaceuticals Inc | 0.064M |